Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2022 07:18 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Mandatory notification of trade by primary insider

Oslo, 17 February 2022, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at an average price of NOK 93.66 per share....
February 17, 2022 02:00 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Fourth quarter 2021 result presentation

Oslo, 17 February 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its fourth quarter 2021 results today. The presentation...
February 10, 2022 02:00 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation

Oslo, 10 February 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its fourth quarter 2021...
February 03, 2022 02:00 ET | Source: Ultimovacs ASA

Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study

No safety concerns found in first two dose level cohortsEnables progression to highest dosing level in assessment of Ultimovacs’ second vaccine technology platform Oslo, 3 February 2022: Ultimovacs...
December 15, 2021 02:00 ET | Source: Ultimovacs ASA

First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer

Study assesses impact of UV1 in ovarian cancer maintenance careAddresses unmet medical need among BRCA-negative ovarian cancer patients Enrollment of 184 patients to be coordinated through NSGO-CTU...
December 02, 2021 13:00 ET | Source: Ultimovacs ASA

Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma

Designation covers UV1 in Metastatic Melanoma as sole agent or part of combinationSeven-year market exclusivity after regulatory approval, if received Oslo, 2 December 2021: Ultimovacs ASA...
December 02, 2021 10:30 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Mandatory notification of trade by primary insider

Oslo, 2 December 2021, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at a price of NOK 107.60 per share. Following this...
November 29, 2021 14:15 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Mandatory notification of trade by primary insider

Oslo, 29 November 2021, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at a price of NOK 114.00 per share, and a closely...
November 25, 2021 02:00 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Mandatory notification for close associate

Oslo, Norway, November 25, 2021: Radforsk Investeringsstiftelse, a legal person closely associated with a person discharging managerial responsibilities in Ultimovacs ASA has notified the company of a...
November 11, 2021 02:00 ET | Source: Ultimovacs ASA

Ultimovacs ASA: Third quarter 2021 result presentation

Oslo, 11 November 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its third quarter 2021 results today. The presentation by...